BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zerenex ferric citrate: Phase III data

A double-blind, Japanese Phase III trial in 90 non-dialysis dependent CKD patients with baseline serum phosphorus levels of >=5 mg/dL showed that 1.5-6 g/day Zerenex met the primary endpoint of reducing mean serum phosphorus levels from baseline to week 12 vs. placebo (1.29 mg/dL vs. an increase of 0.06 mg/dL, p<0.0001). Zerenex also met the secondary endpoints of a greater proportion of patients achieving target serum phosphorous levels of 2.5-4.5 mg/dL at week 12 vs. placebo (64.9% vs. 6.9%, p<0.0001) and of reducing median FGF23 levels...

Read the full 410 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >